Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name	KIN-3248
Synonyms
Therapy Description	KIN-3248 is a small molecule pan-FGFR inhibitor with activity against secondary resistance mutations, potentially inhibiting tumor growth (J Clin Oncol 40, 2022 (suppl 4; abstr 461)).

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
KIN-3248		KIN3248\|KIN 3248	FGFR Inhibitor (Pan) 26	KIN-3248 is a small molecule pan-FGFR inhibitor with activity against secondary resistance mutations, potentially inhibiting tumor growth (J Clin Oncol 40, 2022 (suppl 4; abstr 461)).

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 8 of 8 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FGFR2 act mut	Advanced Solid Tumor	predicted - sensitive	KIN-3248	Phase I	Actionable	In a Phase I trial, KIN-3248 treatment demonstrated safety and preliminary activity in patients with advanced solid tumors harboring alterations in FGFR2 or FGFR3, resulting in an objective response rate of 9.25% (5/54, 5 partial responses) and disease control rate of 46% (25/54), with stable disease in 20 patients (PMID: 38602417; NCT05242822).	38602417
FGFR2 fusion	gastroesophageal junction adenocarcinoma	predicted - sensitive	KIN-3248	Phase I	Actionable	In a Phase I trial, KIN-3248 treatment demonstrated safety and preliminary activity in patients with advanced solid tumors harboring alterations in FGFR2 or FGFR3, with an objective response rate of 9.25% (5/54, 5 partial responses (PR)), including 2 PRs in patients with gastroesophageal jucntion cancer harboring a FGFR2 fusion (PMID: 38602417; NCT05242822).	38602417
FGFR3 act mut	Advanced Solid Tumor	predicted - sensitive	KIN-3248	Phase I	Actionable	In a Phase I trial, KIN-3248 treatment demonstrated safety and preliminary activity in patients with advanced solid tumors harboring alterations in FGFR2 or FGFR3, resulting in an objective response rate of 9.25% (5/54, 5 partial responses) and disease control rate of 46% (25/54), with stable disease in 20 patients (PMID: 38602417; NCT05242822).	38602417
FGFR2 G542A FGFR2 V564L FGFR2 amp	stomach cancer	sensitive	KIN-3248	Preclinical - Pdx	Actionable	In a preclinical study, KIN-3248 treatment inhibited tumor growth in a gastric cancer patient derived xenograft (PDX) model harboring FGFR2 V564L and G542A with FGFR2 amplification (PMID: 38267212).	38267212
FGFR3 S249C FGFR3 N540K	urinary bladder cancer	sensitive	KIN-3248	Preclinical - Cell culture	Actionable	In a preclinical study, KIN-3248 inhibited viability of a bladder cancer cell line harboring FGFR3 S249C and expressing FGFR3 N540K in culture (PMID: 38437671).	38437671
FGFR3 S249C FGFR3 V555M	urinary bladder cancer	sensitive	KIN-3248	Preclinical - Cell culture	Actionable	In a preclinical study, KIN-3248 inhibited viability of a bladder cancer cell line harboring FGFR3 S249C and expressing FGFR3 V555M in culture (PMID: 38437671).	38437671
FGFR2 N550H	Advanced Solid Tumor	predicted - sensitive	KIN-3248	Preclinical - Biochemical	Actionable	In a preclinical study, KIN-3248 inhibited kinase activity of FGFR2 N550H in an in vitro assay (PMID: 38437671).	38437671
FGFR3 K650M	Advanced Solid Tumor	predicted - sensitive	KIN-3248	Preclinical - Biochemical	Actionable	In a preclinical study, KIN-3248 inhibited kinase activity of FGFR3 K650M in an in vitro assay (PMID: 38437671).	38437671

Showing 1 to 8 of 8 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT05242822	Phase I	KIN-3248	A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations	Terminated	USA \| ESP \| DNK	3

Showing 1 to 1 of 1 entries

Filter rows:

Additional content available in CKB BOOST